Tigecycline-induced acute pancreatitis: about two cases and review of the literature.

Abstract

Tigecycline (formerly CAR-936, Tygacyl) is the first glycylcycline antibiotic available for clinical use. It has an expanded broad-spectrum antibiotic activity. Phase III studies have identified gastrointestinal side-effects, especially nausea and vomiting, as the most common adverse events. Few cases of acute pancreatitis (AP) have been described in the literature. We report two new cases of mild tigecycline-induced pancreatitis. Tigecycline was given for soft-tissue infection in both cases. Symptoms such as nausea, vomiting and mostly abdominal pain occurred within 5 days after starting Tigecycline. Pancreatic enzymes elevation occurred five to six days after initiation of treatment, and resolved within a week after drug-discontinuation. Diagnosis of mild pancreatitis was confirmed after performing CT-Scan of the abdomen in both cases. We take this opportunity to review the literature about this potentially serious side-effect induced by tigecycline.

• Authors: J-C Marot, S Jonckheere, H Munyentwali, L Belkhir, B Vandercam, J C Yombi
• Journal: Acta clinica Belgica (Acta Clin Belg) 2012 May-Jun Vol. 67 Issue 3 Pg. 229-32 ISSN: 1784-3286 [Print] England
• PMID: 22897076 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Tigecycline
• Lipase
• Amylases
• Minocycline

Topics

• Amylases (analysis)
• Anti-Bacterial Agents (adverse effects)
• Humans
• Lipase (analysis)
• Male
• Middle Aged
• Minocycline (adverse effects, analogs & derivatives)
• Pancreatitis (chemically induced)
• Soft Tissue Infections (drug therapy)
• Tigecycline